The evidence supporting tadalafil for sexual arousal problems after menopause is insufficient to establish it as a standard treatment. Tadalafil may theoretically increase clitoral and vulvar blood flow through PDE5 inhibition, but Cialis labeling states that the erectile-dysfunction product is not indicated for females. No FDA-approved tadalafil dose has been established for postmenopausal arousal difficulty, reduced genital sensation, vaginal dryness, orgasm problems, or low sexual desire.

The Direct Answer

Tadalafil should not be considered a routine postmenopausal sexual-arousal treatment.

Its mechanism may be relevant to a narrow subgroup of women whose primary problem involves reduced genital vascular response despite preserved desire and adequate stimulation. However, the available evidence does not establish:

• which postmenopausal women might benefit;

• whether benefits exceed placebo effects;

• whether daily or as-needed dosing is preferable;

• which dose should be used;

• how long treatment should continue;

• whether improved blood flow produces meaningful sexual satisfaction;

• whether benefits outweigh systemic adverse effects.

A clinician prescribing tadalafil specifically for female sexual arousal would be using it off label. Off-label use can be medically legitimate in selected circumstances, but it should not be confused with an approved or well-established treatment.

Sexual Arousal Is Not One Single Process

Sexual arousal has both subjective and physical components.

Subjective arousal

This is the mental experience of feeling sexually excited, engaged, receptive, or interested.

Genital arousal

This may include:

• clitoral engorgement;

• vulvar fullness;

• increased genital warmth;

• vaginal lubrication;

• heightened physical sensitivity.

A woman may experience mental desire without a strong genital response. Another may have physical lubrication but little subjective excitement. Some women experience both problems simultaneously.

Tadalafil mainly influences vascular signaling. It does not directly create sexual interest, emotional engagement, attraction, or motivation.

How Tadalafil Might Affect Genital Arousal

Tadalafil inhibits phosphodiesterase type 5, or PDE5.

PDE5 breaks down cyclic guanosine monophosphate, which participates in nitric oxide–mediated smooth-muscle relaxation. In men, preserving this signaling supports penile blood flow during sexual stimulation.

Female genital tissues also respond to neurological and vascular signaling. In theory, tadalafil could support:

• clitoral blood filling;

• vulvar engorgement;

• genital warmth;

• sensitivity during direct stimulation.

However, a biologically plausible mechanism is not equivalent to demonstrated clinical effectiveness. A medication can increase a physiological measurement without meaningfully improving pleasure, distress, orgasm, relationship satisfaction, or overall sexual function.

Tadalafil-Specific Evidence in Women Is Limited

One small published study evaluated tadalafil 5 mg daily in premenopausal women with type 1 diabetes and genital arousal disorder. The authors reported improvement in subjective sexual measures, but the study had major limitations: it involved a small group, lacked a placebo control, and did not study postmenopausal women.

This study cannot establish that tadalafil works for sexual arousal problems after menopause because:

• the participants were premenopausal;

• they had type 1 diabetes;

• the sample was small;

• treatment was not compared with placebo;

• menopausal vaginal tissue changes were not the treatment target.

Evidence involving sildenafil, another PDE5 inhibitor, also cannot automatically validate tadalafil. The medicines differ in pharmacokinetics, formulation, dosing, and duration of systemic exposure.

Why Menopause Changes the Clinical Question

Menopause can affect sexual function through several pathways at once.

Potential contributors include:

• declining estrogen;

• vulvovaginal tissue thinning;

• reduced elasticity;

• vaginal dryness;

• pain during penetration;

• altered genital sensitivity;

• sleep disruption;

• hot flashes;

• mood changes;

• medication use;

• chronic illness;

• relationship factors.

The Menopause Society emphasizes that sexual concerns at midlife may involve desire, arousal, orgasm, and pain, with each domain requiring a different assessment.

A vascular medicine is unlikely to solve the problem when pain, tissue changes, low desire, inadequate stimulation, or medication-related neurological effects are dominant.

Genitourinary Syndrome of Menopause Is Often Misidentified as Poor Arousal

Reduced estrogen can produce genitourinary syndrome of menopause, or GSM.

Symptoms may include:

• vaginal dryness;

• burning;

• irritation;

• tissue fragility;

• reduced elasticity;

• painful intercourse;

• urinary discomfort;

• recurrent urinary symptoms.

A woman may describe these experiences as “not becoming aroused,” even when the central problem is painful, dry, or fragile tissue.

ACOG notes that vaginal dryness is common after menopause and may cause irritation, burning, and pain during intercourse.

Tadalafil does not restore estrogen-dependent vaginal tissue. Increasing blood flow cannot reliably reverse tissue thinning, inflammation, or loss of elasticity.

Tadalafil Is Not a Treatment for Vaginal Dryness

Lubrication is influenced by sexual stimulation, hormonal status, tissue condition, medication use, and comfort.

Tadalafil may theoretically affect vascular transudation, but it is not an approved treatment for menopausal vaginal dryness.

More directly relevant options may include:

• lubricants during sexual activity;

• regular vaginal moisturizers;

• low-dose vaginal estrogen;

• vaginal prasterone;

• oral ospemifene.

The appropriate choice depends on symptom severity, medical history, cancer history, bleeding, cardiovascular risk, and personal preference.

Lubricants and Vaginal Moisturizers

Lubricants reduce friction during sexual activity. Vaginal moisturizers are used regularly to help maintain moisture between sexual encounters.

They may be appropriate when the main symptoms are:

• dryness;

• friction;

• irritation;

• mild penetration discomfort.

ACOG and The Menopause Society identify lubricants and vaginal moisturizers as initial options for menopause-related dryness and sexual discomfort.

These products do not directly increase desire, but reducing discomfort may allow normal arousal to develop more easily.

Low-Dose Vaginal Estrogen

Low-dose vaginal estrogen can treat menopausal tissue changes more directly by improving vaginal moisture, elasticity, and tissue condition.

ACOG notes that topical estrogen may improve vaginal or vulvar dryness and painful intercourse within several weeks, although the exact response time varies.

Vaginal estrogen products have their own contraindications, warnings, and prescribing considerations. A history of estrogen-dependent cancer or unexplained postmenopausal bleeding requires individualized professional assessment.

Vaginal Prasterone

Prasterone vaginal inserts are FDA approved for moderate to severe dyspareunia caused by vulvar and vaginal atrophy due to menopause.

The approved product contains 6.5 mg of prasterone in each vaginal insert. It is intended to treat menopause-related painful intercourse rather than generalized low desire or every form of arousal disorder.

A woman whose arousal decreases because penetration is painful may experience secondary improvement when the pain is treated, but this differs from using tadalafil to increase genital blood flow.

Ospemifene

Ospemifene is an oral selective estrogen receptor modulator approved for:

• moderate to severe dyspareunia due to menopausal vulvar and vaginal atrophy;

• moderate to severe vaginal dryness due to menopausal vulvar and vaginal atrophy.

Its approved dose is not a substitute for tadalafil, and it carries clinically important warnings and contraindications, including considerations involving thromboembolic events and estrogen-sensitive conditions.

Treatment should be selected according to the diagnosed symptom rather than the general label of “female sexual dysfunction.”

Tadalafil Does Not Directly Treat Low Sexual Desire

Low desire and impaired genital arousal are different problems.

A woman with low desire may experience:

• few sexual thoughts;

• little motivation to initiate sex;

• reduced interest across situations;

• difficulty becoming mentally engaged;

• distress about the loss of interest.

Tadalafil acts on vascular PDE5 signaling and does not directly modify the central neurotransmitter pathways used to regulate sexual motivation.

A lack of desire should therefore not be treated by increasing tadalafil from 5 mg to 10 mg or 20 mg.

Flibanserin Is Directed at a Different Symptom

Flibanserin is indicated for acquired, generalized hypoactive sexual desire disorder in eligible women younger than 65, including naturally postmenopausal women under the current US label.

The diagnosis requires low desire that causes marked distress or interpersonal difficulty and is not better explained by another medical or psychiatric condition, relationship problems, medication, or substance use.

Flibanserin treats low desire, not isolated vaginal dryness or a purely genital vascular-arousal problem. It also has important risks involving hypotension, syncope, alcohol timing, liver impairment, and CYP3A4 interactions.

Its existence does not mean every postmenopausal woman with reduced sexual interest needs medication.

Bremelanotide Is Not Approved After Menopause

Bremelanotide is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

Its prescribing information specifically states that it is not indicated for postmenopausal women.

It should not be presented as a postmenopausal alternative to tadalafil without acknowledging this restriction.

Antidepressants Can Affect Arousal and Orgasm

SSRIs, SNRIs, and some other psychiatric medicines may contribute to:

• reduced desire;

• diminished genital sensation;

• delayed orgasm;

• absent orgasm;

• reduced lubrication;

• muted subjective arousal.

Tadalafil may theoretically address a vascular component but cannot reliably reverse central serotonin-related effects.

A woman should not abruptly stop psychiatric medication or add an unapproved sexual-enhancement product. Options may include dose review, timing changes, switching medication, or another strategy coordinated with the prescribing clinician.

Diabetes and Vascular Disease

Diabetes may affect female sexual response through:

• vascular dysfunction;

• autonomic nerve injury;

• reduced genital sensation;

• vaginal dryness;

• medication burden;

• psychological effects of chronic illness.

The limited tadalafil study in women involved premenopausal participants with type 1 diabetes, which suggests a possible research direction but does not establish routine treatment.

A postmenopausal woman with diabetes may have overlapping vascular, neurological, and GSM-related symptoms. Treating only blood flow may leave the dominant problem unresolved.

Pelvic Surgery and Neurological Causes

Reduced genital sensation or arousal may follow:

• pelvic surgery;

• spinal cord disease;

• multiple sclerosis;

• peripheral neuropathy;

• pelvic radiation;

• nerve injury.

Tadalafil cannot repair damaged nerves.

A vascular response requires intact sensory and neurological pathways. If reduced sensation is the main complaint, neurological and pelvic evaluation may be more useful than escalating a PDE5 inhibitor.

Sexual Stimulation Still Matters

Tadalafil does not create an automatic genital response.

Any potential effect would still depend on adequate sexual stimulation and nitric oxide signaling.

After menopause, stimulation may need to be:

• longer;

• more direct;

• focused on the clitoris;

• less rushed;

• accompanied by lubricant;

• adjusted to avoid painful areas.

A medication should not substitute for communication, adequate stimulation, comfort, and consent.

Pain Suppresses Arousal

Pain can interrupt arousal before a vascular medicine has any meaningful opportunity to help.

When sexual activity is anticipated as painful, the nervous system may produce:

• pelvic-floor tightening;

• reduced lubrication;

• avoidance;

• anxiety;

• difficulty concentrating on pleasurable sensation.

Potential causes include GSM, pelvic-floor dysfunction, vulvodynia, infection, dermatologic disease, endometriosis, scar tissue, or pelvic organ problems.

ACOG identifies vaginal estrogen, dilators, and pelvic-floor physical therapy among treatments that may be considered according to the specific sexual problem.

There Is No Approved Female Tadalafil Dose

The commonly discussed tadalafil regimens come from male erectile-dysfunction treatment:

• 2.5 mg once daily;

• 5 mg once daily;

• 10 mg as needed;

• 20 mg as needed.

None is an approved postmenopausal arousal regimen.

It is not scientifically valid to assume that:

• 5 mg is a safe female starting dose;

• 10 mg is appropriate before sex;

• 20 mg should be tried after a weak response;

• daily dosing provides better spontaneity;

• a dose effective in men will produce an equivalent female response.

The correct dose cannot be inferred simply from body size or menopausal status.

Daily Tadalafil Creates Continuous Exposure

Tadalafil has a mean terminal half-life of approximately 17.5 hours.

With daily treatment, some drug remains when the next dose is taken. Steady-state exposure develops over several days. This creates continuous potential for:

• headache;

• indigestion;

• flushing;

• nasal congestion;

• back pain;

• muscle pain;

• dizziness;

• hypotension;

• drug interactions.

These systemic effects may occur even when no improvement in sexual arousal is experienced.

A daily regimen should not be described as safer merely because each individual tablet contains fewer milligrams.

As-Needed Tadalafil Also Has Limitations

An as-needed dose produces a higher single exposure around a planned sexual encounter.

Potential disadvantages include:

• headache during sexual activity;

• flushing;

• dizziness;

• indigestion;

• pressure to produce a sexual response after taking the tablet;

• unsafe redosing when no benefit appears quickly.

Tadalafil reaches peak concentration over a broad time range and remains in the body long after the immediate encounter. A weak response after one or two hours is not a reason to take another tablet.

Nitrates Are Strictly Contraindicated

Tadalafil must not be combined with organic nitrates or recreational nitrites.

Examples include:

• nitroglycerin;

• isosorbide mononitrate;

• isosorbide dinitrate;

• amyl nitrite;

• butyl nitrite;

• poppers.

The combination can cause a profound and potentially life-threatening fall in blood pressure. Tadalafil is also contraindicated with guanylate cyclase stimulators such as riociguat.

Postmenopausal women may have a greater likelihood of cardiovascular medication use, making a complete medication review essential.

Blood Pressure Medication and Alcohol

Tadalafil may add to the effects of:

• alpha blockers;

• calcium-channel blockers;

• ACE inhibitors;

• angiotensin receptor blockers;

• other antihypertensive medicines;

• substantial alcohol consumption.

Possible symptoms include:

• dizziness;

• weakness;

• blurred vision;

• lightheadedness after standing;

• fainting.

A woman with low baseline blood pressure, recurrent dizziness, or several antihypertensive medicines should not experiment with an online Female Cialis product.

CYP3A4 Drug Interactions

Tadalafil is metabolized mainly through CYP3A4.

Strong inhibitors can substantially increase exposure. Relevant examples include certain:

• azole antifungals;

• antiviral medicines;

• HIV treatments;

• macrolide antibiotics.

Under approved male erectile-dysfunction instructions, strong CYP3A4 inhibition requires major limits on tadalafil dose and frequency. These instructions do not establish a female dosage, but they demonstrate why apparently low-dose experimentation may still produce unexpectedly high exposure.

Kidney and Liver Function

Significant kidney or liver impairment can change tadalafil clearance and dosing restrictions.

Once-daily tadalafil is not recommended under some severe renal conditions, while as-needed use may require a lower dose and a substantially longer interval. Severe liver impairment also creates important limitations.

A woman with chronic kidney disease, liver disease, or multiple medications should not use a generic online dosing chart.

Product Authenticity Is a Separate Risk

“Female Cialis” is not the name of an FDA-approved treatment for postmenopausal sexual arousal disorder.

Products sold under this description may have uncertain:

• tadalafil content;

• dose accuracy;

• purity;

• manufacturing standards;

• storage conditions;

• additional undeclared ingredients.

In April 2026, FDA reported that laboratory testing of a product marketed for female sexual enhancement found undeclared sildenafil, tadalafil, and flibanserin. Combining undisclosed prescription ingredients can create unpredictable interactions and adverse effects.

An online product should not be considered safe simply because its label claims a low tadalafil dose or uses female-focused branding.

When Immediate Medical Care Is Required

Seek urgent medical care after tadalafil exposure for:

• chest pain;

• fainting or collapse;

• severe breathing difficulty;

• sudden vision loss;

• sudden hearing loss;

• facial or throat swelling;

• severe confusion;

• one-sided weakness;

• an abnormal or very rapid heartbeat;

• profound hypotension.

Emergency clinicians should be told:

• the product name;

• the claimed dose;

• when it was taken;

• where it was purchased;

• all other medicines and substances used.

What a Proper Clinical Assessment Should Identify

Before considering any medication, the clinician should determine:

• whether desire is present;

• whether subjective excitement develops;

• whether genital sensation is reduced;

• whether lubrication is inadequate;

• whether sex is painful;

• whether orgasm is delayed or absent;

• whether symptoms occur in every situation;

• whether antidepressants or other medicines contribute;

• whether GSM is present;

• whether diabetes, neurological disease, or surgery affects sensation;

• whether relationship, stress, or mood factors are significant.

The treatment should be directed at the dominant mechanism rather than the broad complaint that arousal is “not the same after menopause.”

The Practical Bottom Line

Tadalafil has a plausible vascular mechanism that might influence genital blood flow, but it is not an established treatment for sexual arousal problems after menopause.

The tadalafil-specific evidence in women is sparse. A small uncontrolled study suggested possible benefit in premenopausal women with type 1 diabetes, but it cannot establish effectiveness in postmenopausal women. There is no FDA-approved female dose, schedule, or treatment duration.

Postmenopausal sexual-arousal difficulty should be divided into its actual components:

• vaginal dryness and painful sex may respond to lubricants, moisturizers, vaginal estrogen, prasterone, or ospemifene;

• low desire requires assessment for HSDD and other psychological, medical, relationship, or medication-related causes;

• reduced sensation may require neurological, diabetes, or pelvic-surgery evaluation;

• pelvic-floor dysfunction and pain may require physical therapy or targeted gynecologic treatment.

Tadalafil should not be started, increased, combined with another PDE5 inhibitor, or purchased as Female Cialis without professional evaluation. Nitrate use, cardiovascular medication, low blood pressure, organ impairment, drug interactions, and product authenticity must all be considered.

Disclaimer: This article is for informational purposes only and is not medical advice. Tadalafil and products marketed as Female Cialis should not be used for postmenopausal sexual symptoms without evaluation and supervision by a licensed healthcare professional.